The Board of Directors of Orchidia agreed to increase the company's investments in the field of eye medicines production for the years 2017-2018 to 200 million pounds after increasing the demand for the company's medicines in the local market and export.
Orchidia acquired a market share of 36.8% of the IMS dry eye market, according to the company's data to lead the market with sales of 50 million pounds in the first half of 2017
Orchidia is starting to install the new line of Single Dose Unit (SDU) eye drops which are single-use droplets that are free of preservatives as it will be shipped that produced by Rommelag - Switzerland to Egypt and will begin installation in September 2017.
Orchidia Pharmaceutical Industries obtained the approval of Sudan Ministry of Health to register five of the company's eye drops, as the company obtained the pricing certificates of the 5 products in accordance with the regulations adopted in Sudan.
May 15, 2017, Egypt
Orchidia Pharmaceutical Industries has begun the introduction of Bromoflam in the Egyptian market through Hospitals and Pharmacies.
Bromoflam is a product containing Bromfenac Sodium in a 5 ml eye drop; it is an anti-inflammatory, non-steroidal eye drop characterized by its efficacy in the treatment of pain associated with surgery and eye inflammation pain.
Bromoflam is the first and only eye product in Egypt to contain the active ingredient Bromfenac Sodium.
Orchidia plans to make the Bromoflam the market leader of the as anti-inflammatory non-steroidal eye drops market in Egypt during the coming two years.
Bromoflam is priced at 25 Egyptian pounds for the public.
The Egyptian-American Enterprise Fund (“EAEF”) announced today that it has entered into binding agreements to acquire a significant minority stake in Orchidia Pharmaceutical Industries the leading Egyptian ophthalmic generic medicine manufacturer and one of the fastest growing pharmaceutical companies in Egypt.
Orchidia Pharmaceutical Company launched its two products in Sudan.
Tears Guard and Poly-fresh eye drops are now available in the Sudanese market. It is expected to launch more products during the year 2018.
The remarkable team has successfully installed the Romelage machines (SDU) in the production area which initiated the first phase of the assembly process. This machine will contribute to the technological development of the eye drops filling for the local and international markets.
The Egyptian Ophthalmological Soceity honored Dr. Ossama Abbasو the Chief Executive Officer of Orchidia Pharmaceutical company, for his efforts in the CME programs (continued medical education ) and for “Enek Fe Enena “
We are glad to announce the beginning of Orchidia Wet-lab at Orchidia Pharmaceutical premises.
The wave one (from 1 / 4 till 15/5/2018) will cover the basic course in Phaco Emulsification (Cataract Surgery).
For registration call the company medical representative in your Area.
On Thursday, 19/7/2018, the press conference of "Great Minds" second wave initiative has been held at one of the top ranked hotels in Cairo for signing the protocol of cooperation between Orchidia Pharmaceutical company and the Egyptian Association for Continuing Medical Education
Orchidia’s participation in the 2nd international conference of the Gabonese Society of Ophthalmology. The conference was held in Libreville, the Gabonese capital, on 28 and 29 February 2020
The international live webinars "Glaucoma & Neuro-Ophthalmology ", organized by Orchidia Pharmaceutical Industries in cooperation with City Eye Center and the Jordan Ophthalmologists Association.
Cher docteur;
Vous êtes cordialement invité à assister à la réunion internationale en ligne sur le webinaire "Kératite fongique" du Dr El-Nazir Mohamed Adam, organisée par Orchidia Pharmaceutical Industries.
Cher docteur;
Vous êtes invités à assister aux webinaires internationaux en direct de "Rétinopathie diabétique et oculoplastie", organisés par Orchidia Pharmaceutical Industries en coopération avec le centre City Eye et la Jordan Ophthalmologists Association.
The first live webinar of Glaucomatology 2020( Glaucoma CME) “ Tips to a comprehensive Glaucoma Examination, sponsored by Orchidia Pharmaceutical company .
La deuxième session de Glaucomatology 2020 (Glaucoma CME) «Le champ visuel: vers une meilleure compréhension de son importance clinique dans le diagnostic et le suivi du glaucome», parrainé par la société Orchidia Pharmaceutical.
The Third live session of Glaucomatology 2020( Glaucoma CME) “ The Optic Disc in Glaucoma, Clinical Evaluation and OCT Interpretation”, sponsored by Orchidia Pharmaceutical company .
As a part of Orchidia’s global expansion strategy and especially in African continent, we are glad to announce the registration of Orchidia Pharmaceutical Company in the Democratic Republic of Congo
Une nouvelle vague de campagne «Eineak Fi Einena» débutera d'ici janvier 2021
«Enek Fi Enena - عنيك فى عنينا» est l'une de nos campagnes RSE les plus réussies
La pommade oculaire Avazir (Tobramycine 0.3), la nouvelle formule avancée, est l'un de nos nouveaux produits qui est maintenant disponible sur le marché égyptien.
La première réunion scientifique du projet « See The Impact », la première du genre au Moyen-Orient portant sur l'effet des collyres, contenant des conservateurs, sur la surface de l'œil, parrainé par Orchidia.
The 10th Anniversary celebration of Polyfresh Brand in the Egyptian market and overseas. Advancing to a new level to reach patient satisfaction with the highest medical efficacy.
The Export Council of Medical Industries honored Orchidia Pharmaceutical Industries for its role in increasing Egyptian pharmaceutical exports and opening new international markets.
French
English
Arabic
Arabic 
.jpg)
.jpg)
